|
Volumn 19, Issue 9, 1998, Pages 392-394
|
Rocking the foundations of solid tumor growth by attacking the tumor's blood supply
|
Author keywords
[No Author keywords available]
|
Indexed keywords
AE 941;
ANGIOGENESIS INHIBITOR;
ANTINEOPLASTIC AGENT;
CYTOKINE;
DIPHTHERIA TOXIN;
DOXORUBICIN;
FUMAGILLOL CHLOROACETYLCARBAMATE;
GAMMA INTERFERON;
INTEGRIN;
MONOCLONAL ANTIBODY;
MONOCLONAL ANTIBODY LM 609;
PROTEIN ANTIBODY;
SEMAXANIB;
THROMBOSPONDIN 1;
TUMOR NECROSIS FACTOR ALPHA;
UNCLASSIFIED DRUG;
VASCULOTROPIN;
VASCULOTROPIN RECEPTOR;
ANGIOGENESIS;
ANIMAL MODEL;
CANCER IMMUNOLOGY;
CANCER INHIBITION;
CLINICAL ARTICLE;
CLINICAL TRIAL;
ENDOTHELIUM CELL;
HUMAN;
MOUSE;
NONHUMAN;
PHASE 1 CLINICAL TRIAL;
PHASE 2 CLINICAL TRIAL;
PRIORITY JOURNAL;
REVIEW;
SOLID TUMOR;
TRANSGENIC MOUSE;
TUMOR BLOOD FLOW;
VASCULAR ENDOTHELIUM;
|
EID: 0032171619
PISSN: 01675699
EISSN: None
Source Type: Journal
DOI: 10.1016/S0167-5699(98)01314-0 Document Type: Article |
Times cited : (43)
|
References (15)
|